Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study

11/17 Late treatment study

Boari et al, Biosci. Rep., doi:10.1042/BSR20203455 (Peer Reviewed)
Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study

Source PDF Share Tweet

Retrospective 258 hospitalized patients in Italy showing lower mortality with HCQ treatment, unadjusted relative risk RR 0.455, p<0.001. Data is in the supplementary appendix.

Boari et al., 11/17/2020, retrospective, Italy, Europe, peer-reviewed, 20 authors.

risk of death, 54.5% lower, RR 0.45, p < 0.001, treatment 41 of 202 (20.3%), control 25 of 56 (44.6%).

This study is excluded in meta analysis: unadjusted results with no group details.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 344 studies Meta Analysis

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit